Cargando…
Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients
BACKGROUND: CA 15.3 is elevated in most patients with distant metastatic breast cancer who had prognostic information. The present study was performed to estimate predictive ability of CA 15.3 in assessment of symptomatic metastasis in patients with breast cancer. MATERIALS AND METHODS: During five...
Autores principales: | Bahrami-Ahmadi, Amir, Makarian, Fariborz, Mortazavizadeh, Mohammad R., Yazdi, Mohammad F., Chamani, Mehdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697210/ https://www.ncbi.nlm.nih.gov/pubmed/23826012 |
Ejemplares similares
-
Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.
por: Gion, M., et al.
Publicado: (1994) -
The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.
por: Gion, M., et al.
Publicado: (1991) -
Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases
por: Nicolini, Andrea, et al.
Publicado: (2006) -
Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA?
por: Ginguay, Antonin, et al.
Publicado: (2022) -
Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis
por: Ayati, Narjess, et al.
Publicado: (2013)